Daunorubicin-Cytarabine Liposome

Overview

Cytarabine -daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine ( HY-13605 ) and Daunorubicin ( HY-13062A ) at a fixed synergistic molar ratio of 5:1. Cytarabine -daunorubicin improves secondary acute myeloid leukemia. Cytarabine -daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia.

Application

Products | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Chronic Myelogenous Leukemia | Products > Disease Areas > Myelodysplastic Syndrome | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Others | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Liposome | Products > Signaling Pathways > Drug Derivative

Product Information

• Catalog No.: HY-160952
• CAS No.: 1256639-86-7
• Molecular Formula: C36H42N4O15
• Molecular Weight: 770.74
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source